

Oncology Today with Dr Neil Love: Current Management of and Future Directions in Mesothelioma (Presentation Video)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements is true regarding the single-arm Phase II STELLAR trial of the combination of tumor treating fields (TTFs) with systemic chemotherapy as first-line treatment for unresectable malignant pleural mesothelioma (MPM)?**
 - a. A few treatment-related deaths were reported
 - b. Skin toxicities associated with treatment were mostly severe (Grade ≥ 3)
 - c. Disease control was observed in 97% of patients**
- 2. The combination of nivolumab and ipilimumab recently received FDA approval as first-line treatment for which patients with unresectable MPM?**
 - a. Patients with all histologies**
 - b. Only patients with epithelioid histology
 - c. Only patients with nonepithelioid histology
- 3. Which of the following statements is true regarding the prespecified interim analysis of the Phase III CheckMate 743 trial evaluating nivolumab/ipilimumab versus chemotherapy as first-line treatment for unresectable MPM, which was presented at the 2020 World Conference on Lung Cancer?**
 - a. The doses of nivolumab and ipilimumab were 1 mg/kg and 3 mg/kg respectively
 - b. A statistically significant improvement in overall survival was reported with nivolumab/ipilimumab**
 - c. The biggest relative improvement in overall survival with nivolumab/ipilimumab was for patients with epithelioid histology
- 4. The Phase III MAPS trial that evaluated the addition of bevacizumab to cisplatin and pemetrexed for newly diagnosed MPM demonstrated which of the following outcomes?**
 - a. A significant improvement in overall survival with bevacizumab**
 - b. No significant improvement in overall survival with bevacizumab